XML 49 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 30, 2016
Nov. 09, 2016
Feb. 10, 2016
Jan. 04, 2016
Jan. 31, 2017
Sep. 30, 2016
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration             $ 63,000        
Paid-in-kind interest               $ 1,168,000      
Insulin Put                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration                 $ 10,200,000    
Sanofi-Aventis Deutschland GmbH | Put Option                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Payment for insulin put option         $ 30,600,000       $ 30,600,000    
Aventisub LLC                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Outstanding loan balance forgiven   $ 72,000,000                  
License and Collaboration Agreement with Sanofi                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Profits and losses sharing percentage             35.00%        
Termination date       Apr. 04, 2016              
Maximum secured loan facility                     $ 175,000,000
Senior notes, effective interest rate                     8.50%
Gain on extinguishment of debt   $ 500,000                  
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue - nonrefundable license fee             $ 150,000,000        
Net revenue from collaboration             $ 172,000,000        
Profits and losses sharing percentage             65.00%        
Milestone receivable             $ 25,000,000        
Deferred cost                   $ 13,500,000  
Secured loan facility, amount borrowed     $ 17,900,000             44,500,000  
Secured loan facility, amount owed           $ 71,200,000          
Paid-in-kind interest           $ 5,800,000          
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration             150,000,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration             25,000,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration             25,000,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Deferred revenue - nonrefundable license fee                   17,500,000  
Net revenue from collaboration             17,500,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration             19,400,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Net revenue from collaboration             (64,900,000)        
Company's total portion of loss sharing                   $ 57,700,000  
Receptor                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Nonrefundable payments             400,000        
Nonrefundable option exercise and license fee $ 1,000,000                    
Reduction in research and development expense             400,000        
Deferred revenue - nonrefundable license fee             $ 1,000,000        
Deferred revenue recognition period             4 years        
Net revenue from collaboration             $ 100,000